NEWS

Authors: Anna Howard, Julia Kerr, Monica McLain, Jessie Modlin Oral cancer treatment agents are being prescribed more frequently in many cancer types. In-office dispensing of oral cancer treatment agents has demonstrated clinical benefits and also shown financial benefit to third-party payers. A previous publication estimated over $200,000 in cost savings annually from in-office dispensing solely […]

Oncology Nurse Navigators: Putting the Value in Value-Based Payment Models Lani M. Alison, BSN, MS-HCQ, PCMH CCE Oncology nurse navigators provide the “constant” in what seem to be undulating waves of changes to workflows, the adoption of new technology, the near-weekly onslaught of new drugs, and the need to ensure every nuance of documentation is […]

PAN New Infographic Spotlight: The Medicare Patient’s Journey—Finding Financial Assistance for Prescription Medications When a patient is diagnosed with a serious, chronic or life-threatening illness, the costs of treatment can be daunting—especially for those living on fixed incomes.  Our latest infographic illustrates the journey of Mary, a fictional Medicare patient who searches for financial assistance […]

Written By: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch Download Here Description: Venetoclax therapy requires particular parameters be closely followed to ensure optimal patient outcomes. This PQI will review appropriate risk stratification, dosing, and dispensing procedures.  These risk stratifications create special challenges for the dispensing of venetoclax. Some medium-risk and all high-risk patients may require […]

The purpose of this ASCO Position Statement is to provide a summary of issues our members have raised about the role of PBMs in oncology, to share questions that have surfaced about PBM practices and their impact on physicians and patients, to assert ASCO’s immediate position on key issues, and to highlight areas of concern […]

Mission Statement: The mission of the Department of Pharmacy is to provide high value, patient-centered care. We will promote best practices that drive safe, effective, and timely medication therapy through all transitions of care. We will cultivate collaboration, innovation, education and career growth through employee engagement and practice advancement initiatives.

Mission Statement: Billings Clinic Cancer Center Mission: To provide leading-edge care for patients and their families. Billings Clinic Cancer Center Vision: To be nationally recognized for premier cancer care and the first choice for patients, their families, and referring providers. Billings Clinic Cancer Center Core Values: Optimism: We believe in creating an environment of optimism […]

Mission Statement: Our Family. Caring for Yours. We’ll be there every step of the way. Our physicians and staff are committed to providing friendly, professional, patient-centered care with dignity and respect for all. Missouri Cancer Associates is a full service medical and radiation oncology and hematology practice made up of 14 physicians in Columbia and […]

Mission Statement: Bassett Medical Center is a part of Bassett Healthcare Network, a healthcare system that strives to provide excellence in healthcare to rural communities across eight counties in central New York. Bassett Medical Center is an academic medical center that exists to offer a continuum of care for our patients in all service lines, […]

(Excerpt from drugchannels.net) Patients today are being asked to pay a significant share of prescription costs for more-expensive specialty drugs, because of high coinsurance amounts. Many patients also face a deductible for their prescriptions.These are either a combined medical-pharmacy benefit deductible or an annual prescription drug deductible that was separate from any general annual deductible. […]

PRINCETON, N.J., June 7, 2018 – Taiho Oncology, Inc. today announced that, in an effort to further support access for patients and their LONSURF® treatment, the co-pay for all dose strengths of LONSURF has been reduced from $30 to $0 per treatment cycle. The co-pay reduction, which took effect on May 1, 2018, is available […]

RealGiDo study results showed median time on treatment and time to progression of 18.7 and 20.8 months, respectively, were not impacted by dose modifications with Gilotrif® (afatinib) as first-line therapyGilotrif safety profile observed in real-world setting showed that there were no new safety signals Ridgefield, Conn., May 31, 2018 – Boehringer Ingelheim today announced results […]